Incyte Announces FDA Approval of Jakafi® (ruxolitinib) for Treatment of Chronic Graft-Versus-Host Disease (GVHD)

September 22, 2021 16:30 UTC

Trending Today

Interest rate outlook has changed rapidly

Virtual reality as a lifeline: ‘For some young people it’s the social’

‘We realised we don’t know English, not the way it’s spoken in Ireland’

Plan to spend 85% of corporation tax is ‘risky’ and a ‘shift in policy’, warns watchdog

Incyte Announces FDA Approval of Jakafi® (ruxolitinib) for Treatment of Chronic Graft-Versus-Host Disease (GVHD)

You will receive full, ad-free access to HeraldChronicle.com as well as full access to the Electronic Edition of the newspaper. ONLY $2.99 per month for the first 3 months! Only $3.99 per month after promotional period. OrONLY $33.99 per year for the 1st yearOnly $37.99 per year after promotional period.

Source: The Herald September 22, 2021 16:30 UTC

UN racism meeting recommits to goals but renews old divides

James Rodriguez makes Qatar move after Everton offload Colombian international to Al-Rayyan

Pakistan minister claims threat to New Zealand cricket team "was generated from India"